These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pioglitazone-induced heart failure despite normal left ventricular function. Shah M; Kolandaivelu A; Fearon WF Am J Med; 2004 Dec; 117(12):973-4. PubMed ID: 15629744 [No Abstract] [Full Text] [Related]
5. [Macular oedema due to rosiglitazone treatment in diabetes mellitus]. Asensio-Sánchez VM; Asensio-Sánchez MJ; Gómez-Ramírez V Arch Soc Esp Oftalmol; 2010 Jul; 85(7):246-8. PubMed ID: 21093714 [TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus. Tatti P; Arrigoni F; Longobardi A; Costanza F; Di Blasi P; Merante D Clin Drug Investig; 2008; 28(5):327-32. PubMed ID: 18407718 [TBL] [Abstract][Full Text] [Related]
7. Diabetic macular edema associated with glitazone use. Ryan EH; Han DP; Ramsay RC; Cantrill HL; Bennett SR; Dev S; Williams DF Retina; 2006; 26(5):562-70. PubMed ID: 16770264 [TBL] [Abstract][Full Text] [Related]
9. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Colucciello M Arch Ophthalmol; 2005 Sep; 123(9):1273-5. PubMed ID: 16157815 [No Abstract] [Full Text] [Related]
10. [Diabetic edematous maculopathy associated with rosiglitazone treatment: report of a case]. Nyssen V; Hautenauven F; Lekeu Hinostroza JP; Guagnini AP Bull Soc Belge Ophtalmol; 2009; (313):39-44. PubMed ID: 20108571 [TBL] [Abstract][Full Text] [Related]
11. Macular edema and thiazolidinediones. Colucciello M; Ryan E Arch Ophthalmol; 2010 Dec; 128(12):1630-1; author reply 1631-2. PubMed ID: 21149797 [No Abstract] [Full Text] [Related]
12. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Motola D; Piccinni C; Biagi C; Raschi E; Marra A; Marchesini G; Poluzzi E Drug Saf; 2012 Apr; 35(4):315-23. PubMed ID: 22376166 [TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes". Singh S; Segal JB Arch Intern Med; 2012 Jul; 172(13):1011-3. PubMed ID: 22688825 [No Abstract] [Full Text] [Related]
14. Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones. Liazos E; Broadbent DM; Beare N; Kumar N Diabet Med; 2008 Jul; 25(7):860-2. PubMed ID: 18644073 [TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone or pioglitazone in type 2 diabetes? de Vries CS; Russell-Jones DL BMJ; 2009 Aug; 339():b3076. PubMed ID: 19690344 [No Abstract] [Full Text] [Related]
16. Thiazolidinedione safety. Kung J; Henry RR Expert Opin Drug Saf; 2012 Jul; 11(4):565-79. PubMed ID: 22616948 [TBL] [Abstract][Full Text] [Related]
17. Do thiazolidinediones cause heart failure? A critical review. Tang WH Cleve Clin J Med; 2006 Apr; 73(4):390-7. PubMed ID: 16610400 [TBL] [Abstract][Full Text] [Related]
18. Glitazone use associated with diabetic macular edema. Fong DS; Contreras R Am J Ophthalmol; 2009 Apr; 147(4):583-586.e1. PubMed ID: 19181303 [TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone and the thiazolidinediones: a changing context. Kenny C Prim Care Diabetes; 2007 Dec; 1(4):185-6. PubMed ID: 18632043 [No Abstract] [Full Text] [Related]
20. The rise and fall of rosiglitazone: reply. Slaoui M Eur Heart J; 2010 May; 31(10):1282-4. PubMed ID: 20499440 [No Abstract] [Full Text] [Related] [Next] [New Search]